Stewart Jeffrey Ryan 4
4 · AbbVie Inc. · Filed Mar 20, 2024
Insider Transaction Report
Form 4
AbbVie Inc.ABBV
Stewart Jeffrey Ryan
EVP, CHIEF COMMERCIAL OFFICER
Transactions
- Exercise/Conversion
Common Stock, $0.01 par value
2024-03-18$61.36/sh+26,110$1,602,110→ 119,890 total - Sale
Common Stock, $0.01 par value
2024-03-18$179.03/sh−5,099$912,874→ 88,681 total - Sale
Common Stock, $0.01 par value
2024-03-18$178.85/sh−26,110$4,669,774→ 93,780 total - Sale
Common Stock, $0.01 par value
2024-03-18$178.69/sh−27,740$4,956,861→ 60,941 total - Exercise/Conversion
Option (Right to Buy)
2024-03-18$61.36/sh−26,110$1,602,110→ 0 totalExercise: $61.36From: 2018-02-16Exp: 2027-02-15→ Common Stock (26,110 underlying)
Holdings
- 1,338(indirect: By Trust)
Common Stock, $0.01 par value
Footnotes (5)
- [F1]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $178.85 to $178.95, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $179.00 to $179.11, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $178.60 to $178.87, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The reporting person disclaims beneficial ownership of all securities held by his spouse.
- [F5]Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3.